araris
Germany
acquiredseed
seed
Stage
1
Investors
About
Araris Biotech AG is developing a novel antibody-drug conjugate (ADC) linker technology that allows for the attachment of any drug to an antibody at any desired position, maintaining antibody integrity and improving the therapeutic index.
Explore araris's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.